| 000 | 01770 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250518043702.0 | ||
| 264 | 0 | _c20200214 | |
| 008 | 202002s 0 0 eng d | ||
| 022 | _a1932-6203 | ||
| 024 | 7 |
_a10.1371/journal.pone.0217597 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGlasauer, Saskia | |
| 245 | 0 | 0 |
_aFirst-line tuberculosis drug resistance patterns and associated risk factors in Germany, 2008-2017. _h[electronic resource] |
| 260 |
_bPloS one _c2019 |
||
| 300 |
_ae0217597 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntitubercular Agents _xtherapeutic use |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aChild, Preschool |
| 650 | 0 | 4 | _aDrug Resistance, Multiple, Bacterial |
| 650 | 0 | 4 | _aEmigrants and Immigrants |
| 650 | 0 | 4 |
_aEthambutol _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGermany _xepidemiology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfant |
| 650 | 0 | 4 |
_aIsoniazid _xtherapeutic use |
| 650 | 0 | 4 | _aLogistic Models |
| 650 | 0 | 4 | _aMicrobial Sensitivity Tests |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMycobacterium tuberculosis _xdrug effects |
| 650 | 0 | 4 | _aPrevalence |
| 650 | 0 | 4 | _aPublic Health Surveillance |
| 650 | 0 | 4 |
_aPyrazinamide _xtherapeutic use |
| 650 | 0 | 4 |
_aRifampin _xtherapeutic use |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aStreptomycin _xtherapeutic use |
| 650 | 0 | 4 |
_aTuberculosis, Multidrug-Resistant _xdiagnosis |
| 700 | 1 | _aAltmann, Doris | |
| 700 | 1 | _aHauer, Barbara | |
| 700 | 1 | _aBrodhun, Bonita | |
| 700 | 1 | _aHaas, Walter | |
| 700 | 1 | _aPerumal, Nita | |
| 773 | 0 |
_tPloS one _gvol. 14 _gno. 6 _gp. e0217597 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1371/journal.pone.0217597 _zAvailable from publisher's website |
| 999 |
_c29788407 _d29788407 |
||